Notitia Biotechnologies receives approval from FDA for phase 2A clinical trial in diabetic & prediabetic patients

Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient`s gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a randomized, controlled clinical trial, and the study will be performed in the Tampa Florida area. Enrollment is expected to begin by October, and further information regarding the study is available on clinicaltrials.gov.

For more information regarding Notitia`s Foundation Guild Microbiome R&D Platform, please click here. For more information about the NBT-NM108`s development pipeline, please click here.